Skip to main content
    H

    Harvard Bioscience Inc (HBIO)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $9.08
    +0.17 (+1.91%)

    Market Cap: $40.75M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Harvard Bioscience Inc (HBIO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Harvard Bioscience (HBIO) has a market cap of $40.75M and an enterprise value of $73.04M. Its net debt of $32.30M equals 79.26% of its market cap. It kept -13.20% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 79.26% above the market cap, as debt exceeds cash.

    Market Cap$40.75M
    Enterprise Value$73.04M
    Latest price (Nov 17, 2026)$9.08

    Key Dates

    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.77% in the quarter ended Sep 30, 2026 and shrank 67.66% a year over 2 years.

    Shares Outstanding4.56M
    Shares Change (YoY)+2.36%
    Shares Change (QoQ)+0.77%
    Share Count Growth (2Y CAGR)-67.66%

    Valuation Ratios

    Sales and book value multiples are 0.5x and 8.1x.

    P/S Ratio0.5x
    Forward P/S0.5x
    P/B Ratio8.1x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 118.7x EBITDA.

    EV / Sales0.8x
    EV / EBITDA118.7x

    Price Statistics

    The stock is up 37.66% over 52 weeks and trades 8.35% above its 50-day average.

    Beta (1Y)1.38
    52-Week Change+37.66%
    1-Month Change+12.24%
    3-Month Change+28.25%
    6-Month Change+81.24%
    5-Year Change-88.18%
    10-Year Change-62.92%
    Total Return (1Y)+37.66%
    Total Return (3Y CAGR)-40.35%
    Total Return (5Y CAGR)-34.60%
    Return vs SPY (1Y)+30.21%
    Max Drawdown (1Y)-45.24%
    Max Drawdown (3Y)-94.82%
    Sharpe Ratio (1Y)0.48
    Correlation with SPY (1Y)0.26
    50-Day Average$8.38
    200-Day Average$6.63
    52-Week Range$4.00 to $10.20
    RSI (14 Days)56.5
    Average Volume (20 Days)30.51K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.76x current liabilities, and total debt is 7.28x shareholder equity.

    Current Ratio1.76x
    Quick Ratio0.86x
    Debt / Equity7.28x
    Debt / EBITDA59.83x

    Returns and Efficiency

    Return on invested capital is -10.25% over the last 12 months, against a 5-year average of -23.24%.

    Return on Equity (ROE)-231.22%
    Return on Assets (ROA)-15.68%
    Return on Invested Capital (ROIC)-10.25%
    Return on Capital Employed (ROCE)-9.03%
    ROE (5Y Average)-90.12%
    ROA (5Y Average)-17.96%
    ROIC (5Y Average)-23.24%
    Asset Turnover1.17x
    Inventory Turnover1.66x
    Receivables Turnover6.08x
    Cash Conversion Cycle215 days

    Scores

    HBIO has an Altman Z-Score of -2.50, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-2.50
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $89.41M over the last 12 months is up 2.34% from the 12 months before.

    Revenue$89.41M
    Revenue Growth (YoY)+2.34%
    Gross Profit$51.35M
    Operating Income-$1.59M
    Pretax Income-$12.10M
    Net Income-$11.80M
    EBITDA$621.00K
    EBIT-$4.44M
    Reported EPS (TTM)-$1.79

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 6.79% of the $75.30M in total assets.

    Cash and Equivalents$4.86M
    Total Debt$37.15M
    Net Debt$32.30M
    Net Debt Per Share$7.08
    Working Capital$19.85M
    Shareholder Equity$5.11M
    Book Value Per Share$1.12
    Tangible Book Value-$10.38M
    Total Assets$75.30M
    Total Liabilities$70.19M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.49M of capital spending, operating cash flow left -$3.17M of free cash flow.

    Operating Cash Flow-$681.00K
    Capital Expenditures$2.49M
    Free Cash Flow-$3.17M
    FCF Per Share-$0.70
    Depreciation and Amortization$5.53M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1.78%, against a 5-year average of -13.08%.

    Gross Margin57.43%
    Operating Margin-1.78%
    Pretax Margin-13.53%
    Net Margin-13.20%
    EBITDA Margin0.69%
    EBIT Margin-4.97%
    FCF Margin-3.55%
    Gross Margin (5Y Average)57.05%
    Operating Margin (5Y Average)-13.08%
    Net Margin (5Y Average)-18.07%

    Growth

    Revenue fell 8.60% a year over 3 years.

    Revenue Growth (3Y CAGR)-8.60%
    Revenue Growth (5Y CAGR)-3.25%
    FCF Growth (5Y CAGR)-7.73%
    Book Value Per Share Growth (2Y CAGR)-57.48%

    Revenue and profit by year

    Dividends and Yields

    HBIO does not pay a dividend. Its free cash flow yield is -7.66%.

    FCF Yield-7.66%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-10 reverse split on Mar 16, 2026.

    Last Split DateMar 16, 2026
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 11 similar companies, HBIO has the 9th highest P/S.

    P/S Ratio0.5x vs 2.9x median
    ROIC-10.25% vs -20.19% median
    Revenue Growth (Trailing 4 Quarters, YoY)+2.34% vs +3.93% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 4.66% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+4.66%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About HBIO

    What is HBIO's market cap?

    Harvard Bioscience has a market cap of $40.75M. Its enterprise value, which adds debt and subtracts cash, is $73.04M.

    How many shares of HBIO are outstanding?

    Harvard Bioscience has 4.56M shares outstanding. The count is up 2.36% from a year earlier.

    Does HBIO pay a dividend?

    No. Harvard Bioscience does not pay a dividend.

    How much debt does HBIO have?

    Harvard Bioscience has $37.15M of total debt and $4.86M of cash and equivalents, a net debt position of $32.30M.